Scientists have discovered how to fix sleep disturbances in mice with traumatic brain injuries — a discovery that could lead to help for hundreds of thousands of people who have long-term and debilitating sleep and wakefulness issues after they suffer concussions.
What scientists found helpful was giving the mice something all humans produce from foods in their normal diets — something called branched chain amino acids.
“If further research confirms what this study suggests, we could develop a dietary supplement of these amino acids that could be a viable therapy to help people after a concussion," said Miranda Lim, M.D., Ph.D., a neurologist and sleep medicine specialist at the Portland VA Medical Center and an assistant professor of pulmonary and critical care medicine, neurology and behavioral neuroscience at Oregon Health & Science University. Lim is the first author of the study, published online today in Science Translational Medicine.
Lim performed this research during her sleep medicine fellowship at the University of Pennsylvania. Senior authors on the study are Akiva S. Cohen, Ph.D., a neuroscientist at The Children's Hospital of Philadelphia and Allan I. Pack, M.D., Ph.D., director of the Center for Sleep and Circadian Neurobiology in the Perelman School of Medicine at the University of Pennsylvania.
Nearly 2 million people a year in the United States suffer a traumatic brain injury, including concussion, which is considered a mild traumatic brain injury. Sleep disturbances are common in those with TBI; some studies show up to 72 percent of TBI patients — including those who’ve suffered concussions — have sleep problems.
Sleep problems impair attention and memory formation in TBI patients, who have a higher rate of functional disability and a higher cost of rehabilitation.
“Sleep disturbances, such as excessive daytime sleepiness and nighttime insomnia, disrupt quality of life and can delay cognitive recovery in patients with TBI,” Lim said. Although physicians can relieve the dangerous swelling that occurs after a severe TBI, there are no existing treatments to address the underlying brain damage associated with problems such as impaired memory, learning and sleep patterns.
In their study, the scientists compared mice with mild TBI to uninjured mice. They found that injured mice were much less able to stay awake for sustained periods of time. The scientists also found that the orexin neurons in the brains of injured mice were much less active than the same neurons in uninjured mice. Orexin neurons help to maintain wakefulness, in mice and in humans. Human studies have shown decreased orexin levels in the spinal fluid of people who have suffered a traumatic brain injury.
Based on prior research, the scientists gave the injured mice a dietary therapy of branched chain amino acids — which humans get most often through foods high in protein, including red meat, poultry and eggs. Branched chain amino acids are the building blocks of neurotransmitters, the chemicals released by neurons in the brain. Like the oil in a car engine, branched chain amino acids keep neurons running smoothly and boost neuron excitability. The branched chain amino acids restored the orexin neurons in the injured mice to a normal activity level, and improved wakefulness.
“These results in an animal model provide a proof-of-principle for investigating this dietary intervention as a treatment for TBI patients,” said Cohen. “If a dietary supplement can improve sleeping and waking patterns as well as cognitive problems, it could help brain-injured patients regain crucial functions.”
The scientists note that human patients with a variety of disorders have been treated with branched chain amino acid therapy for up to two years without adverse effects, so with further study it may prove to be a viable therapy for sleep problems in TBI patients. Cohen cautioned, however, that current evidence does not support TBI patients medicating themselves with commercially available amino acid supplements.
The National Institutes of Health (grants HL007713, HL111725-01A1, NS069629 and HD059288) supported the study, as well as the University of Pennsylvania Department of Medicine/Measey Research Fellowship. Cohen and the Children’s Hospital of Philadelphia hold a provisional U.S. patent for the use of branched chain amino acids as a therapy for traumatic brain injury.
About the OHSU Brain Institute
The Oregon Health & Science University Brain Institute is a national neuroscience leader in patient care, research and education. With more than 1,000 brain scientists and specialists, OHSU is home to one of the largest communities of brain and central nervous system experts in the nation. OHSU Brain Institute scientists have won national recognition for breaking new ground in understanding Alzheimer’s disease and for discoveries that have led to new treatments for Parkinson’s disease, multiple sclerosis, stroke and other brain disorders and diseases.
Oregon Health & Science University is a nationally prominent research university and Oregon’s only public academic health center. It serves patients throughout the region with a Level 1 trauma center and nationally recognized Doernbecher Children’s Hospital. OHSU operates dental, medical, nursing and pharmacy schools that rank high both in research funding and in meeting the university’s social mission. OHSU’s Knight Cancer Institute helped pioneer personalized medicine through a discovery that identified how to shut down cells that enable cancer to grow without harming healthy ones. OHSU Brain Institute scientists are nationally recognized for discoveries that have led to a better understanding of Alzheimer’s disease and new treatments for Parkinson’s disease, multiple sclerosis and stroke. OHSU’s Casey Eye Institute is a global leader in ophthalmic imaging, and in clinical trials related to eye disease.
Todd Murphy | EurekAlert!
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Materials Sciences
08.12.2016 | Materials Sciences
08.12.2016 | Physics and Astronomy